Why It Matters
B. Braun Medical Inc. disclosed lobbying in the third quarter of 2026 on Food and Drug Administration (FDA) issues, generic pharmaceutical and medical device issues, drug and device shortage issues, and pharmacy issues including the Drug Quality and Security Act and 503A and 503B pharmacy issues.
By the Numbers
B. Braun's in-house filing for the third quarter of 2026 reports $116,500 in lobbying.
Alicia Mica, Director of Government Relations, is the sole lobbyist named on the filing, with no prior congressional staff experience listed.
The Agenda
The filing names the Drug Quality and Security Act by title and lists "503A and 503B pharmacy issues" among its topics.
FDA has stated that federal law may allow compounding when a drug appears on its shortage list, while Section 503A restricts compounded drugs that are essentially copies of commercially available products, subject to specified exceptions.
FDA published its Medical Devices Quality System Regulation Amendments final rule on Feb. 2, 2024, with an effective date of Feb. 2.
The Commerce Department opened a Section 232 national-security investigation into imports of medical equipment and devices, initiated April 1, 2025.
Access the Legis1 platform for comprehensive political news, data, and insights
Spot something wrong? Report an issue with this article